Charles M. Perou - Publications

Bioinformatics & Computational Biology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Bioinformatics, Genetics, Oncology

261 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Allott EH, Shan Y, Chen M, Sun X, Garcia-Recio S, Kirk EL, Olshan AF, Geradts J, Earp HS, Carey LA, Perou CM, Pfeiffer RM, Anderson WF, Troester MA. Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. Breast Cancer Research and Treatment. PMID 31535320 DOI: 10.1007/s10549-019-05442-2  0.44
2019 Waks AG, Stover DG, Guerriero JL, Dillon DA, Barry WT, Gjini E, Hartl CA, Lo WT, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, ... ... Perou CM, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31061067 DOI: 10.1158/1078-0432.CCR-19-0173  0.64
2019 Jiang Y, Zhang Y, Leung JY, Fan C, Popov KI, Su S, Qian J, Wang X, Holtzhausen A, Ubil E, Xiang Y, Davis I, Dokholyan NV, Wu G, Perou CM, et al. MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. Nature Communications. 10: 1515. PMID 30944303 DOI: 10.1038/s41467-019-09233-7  0.52
2019 Wong KY, Fan C, Tanioka M, Parker JS, Nobel AB, Zeng D, Lin DY, Perou CM. I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. Genome Biology. 20: 52. PMID 30845957 DOI: 10.1186/s13059-019-1640-4  0.8
2019 Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Research : Bcr. 21: 36. PMID 30841919 DOI: 10.1186/s13058-019-1123-2  0.8
2019 Mose LE, Perou CM, Parker JS. Improved Indel Detection in DNA and RNA via Realignment with ABRA2. Bioinformatics (Oxford, England). PMID 30649250 DOI: 10.1093/bioinformatics/btz033  0.8
2019 Williams LA, Hoadley KA, Nichols HB, Geradts J, Perou CM, Love MI, Olshan AF, Troester MA. Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. Cancer Causes & Control : Ccc. PMID 30617775 DOI: 10.1007/s10552-018-1121-1  0.64
2018 Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, et al. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30498031 DOI: 10.1073/pnas.1810598115  0.52
2018 Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Medicine. 10: 86. PMID 30497520 DOI: 10.1186/s13073-018-0597-3  0.52
2018 Hollern DP, Contreras CM, Dance-Barnes S, Silva GO, Pfefferle AD, Xiong J, Darr DB, Usary J, Mott KR, Perou CM. A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer. Breast Cancer Research and Treatment. PMID 30484104 DOI: 10.1007/s10549-018-5061-y  0.56
2018 Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, ... ... Perou CM, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 7: e1490854. PMID 30386679 DOI: 10.1080/2162402X.2018.1490854  0.64
2018 An Y, Adams JR, Hollern DP, Zhao A, Chang SG, Gams MS, Chung PED, He X, Jangra R, Shah JS, Yang J, Beck LA, Raghuram N, Kozma KJ, Loch AJ, ... ... Perou CM, et al. Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast. Cell Reports. 25: 702-714.e6. PMID 30332649 DOI: 10.1016/j.celrep.2018.09.056  0.56
2018 Couture HD, Williams LA, Geradts J, Nyante SJ, Butler EN, Marron JS, Perou CM, Troester MA, Niethammer M. Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. Npj Breast Cancer. 4: 30. PMID 30182055 DOI: 10.1038/s41523-018-0079-1  0.44
2018 Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, ... ... Perou CM, et al. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports. 24: 1434-1444.e7. PMID 30089255 DOI: 10.1016/j.celrep.2018.07.009  0.64
2018 Sharma P, López-Tarruella S, Garcia-Saenz JA, Khan QJ, Gomez H, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, ... ... Perou CM, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30061361 DOI: 10.1158/1078-0432.CCR-18-0585  0.32
2018 Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry NL, Tolaney S, Dang CT, Krop I, Harris LN, ... ... Perou CM, et al. Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037817 DOI: 10.1158/1078-0432.CCR-17-3431  0.8
2018 Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, ... ... Perou CM, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science (New York, N.Y.). 361: 290-295. PMID 30026228 DOI: 10.1126/science.aap8411  0.8
2018 Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA. TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. Npj Breast Cancer. 4: 13. PMID 29951581 DOI: 10.1038/s41523-018-0067-5  0.64
2018 Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M, Prat A. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews. 67: 63-70. PMID 29763779 DOI: 10.1016/j.ctrv.2018.04.015  0.32
2018 Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, ... ... Perou CM, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine. PMID 29713086 DOI: 10.1038/s41591-018-0009-7  0.64
2018 Puvanesarajah S, Nyante SJ, Kuzmiak CM, Chen M, Tse CK, Sun X, Allott EH, Kirk EL, Carey LA, Perou CM, Olshan AF, Henderson LM, Troester MA. PAM50 and risk of recurrence scores for interval breast cancers. Cancer Prevention Research (Philadelphia, Pa.). PMID 29622545 DOI: 10.1158/1940-6207.CAPR-17-0368  0.44
2018 Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, ... ... Perou CM, et al. Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 556: 135. PMID 29620732 DOI: 10.1038/nature26162  0.4
2018 Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, ... ... Perou CM, et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. The Journal of Clinical Investigation. PMID 29480819 DOI: 10.1172/JCI96153  0.8
2018 Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, ... ... Perou CM, et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. PMID 29414946 DOI: 10.1038/nature25465  0.4
2018 Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, ... ... Perou CM, et al. Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Research : Bcr. 20: 12. PMID 29409530 DOI: 10.1186/s13058-018-0939-5  0.44
2018 Echavarría I, López-Tarruella S, Picornell AC, Garcia-Saenz JA, Jerez-Gilarranz Y, Hoadley KA, Gomez H, Moreno F, Del Monte-Millán M, Marquez-Rodas I, Alvarez EL, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, ... ... Perou CM, et al. Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29378733 DOI: 10.1158/1078-0432.CCR-17-1912  0.64
2018 Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, ... ... Perou CM, et al. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. Journal of the National Cancer Institute. 110. PMID 28859290 DOI: 10.1093/jnci/djx135  0.64
2017 Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, ... Perou CM, et al. Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule. Npj Precision Oncology. 1. PMID 29657983 DOI: 10.1038/s41698-017-0028-8  0.4
2017 Parada H, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, Perou CM, Olshan AF, Troester MA. Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study. Breast Cancer Research : Bcr. 19: 131. PMID 29228969 DOI: 10.1186/s13058-017-0914-6  0.44
2017 McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. PMID 29153866 DOI: 10.1016/j.clbc.2017.10.014  0.4
2017 Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, Perou CM, Love MI, Olshan AF, Troester MA. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes & Control : Ccc. PMID 29124544 DOI: 10.1007/s10552-017-0977-9  0.64
2017 Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM, Vincent BG, Serody JS. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. The Journal of Clinical Investigation. PMID 28825599 DOI: 10.1172/JCI90499  0.8
2017 O'Flanagan CH, Rossi EL, McDonell SB, Chen X, Tsai YH, Parker JS, Usary J, Perou CM, Hursting SD. Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer. Npj Breast Cancer. 3: 26. PMID 28748213 DOI: 10.1038/s41523-017-0027-5  0.8
2017 Bower JJ, Vance LD, Psioda M, Smith-Roe SL, Simpson DA, Ibrahim JG, Hoadley KA, Perou CM, Kaufmann WK. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. Npj Breast Cancer. 3: 9. PMID 28649649 DOI: 10.1038/s41523-017-0009-7  0.64
2017 Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, ... ... Perou CM, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. Jama Oncology. PMID 28472234 DOI: 10.1001/jamaoncol.2017.0595  0.64
2017 Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, ... ... Perou CM, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances. 3: e1600957. PMID 28439535 DOI: 10.1126/sciadv.1600957  0.56
2017 Silva GO, Siegel MB, Mose LE, Parker JS, Sun W, Perou CM, Chen M. SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling. Genome Biology. 18: 66. PMID 28390427 DOI: 10.1186/s13059-017-1193-3  0.8
2017 Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martínez P, Gonzalez P, Hewitt S, He X, Perou CM, Molinolo A, Gibbons L, Abba MC, Gass H, Lanari C. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness. Journal of the National Cancer Institute. 109. PMID 28376177 DOI: 10.1093/jnci/djw317  0.56
2017 Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28341226 DOI: 10.1016/j.jtho.2017.03.010  0.48
2017 Cejalvo JM, Martínez de Dueñas E, Galvan P, García-Recio S, Burgués Gasión O, Paré L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Muñoz M, Nuciforo P, Vidal M, Pérez RM, ... ... Perou CM, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Research. PMID 28249905 DOI: 10.1158/0008-5472.CAN-16-2717  0.32
2017 Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Research and Treatment. PMID 28176176 DOI: 10.1007/s10549-017-4139-2  0.8
2017 Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, ... ... Perou CM, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.CD-16-0653  0.8
2017 Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 14: e1002222. PMID 28068332 DOI: 10.1371/journal.pmed.1002222  0.8
2016 Troester MA, Hoadley KA, D'Arcy M, Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen H, Wilkerson MD, Sandhu R, Johnson NB, Allison KH, Beck AH, Yau C, ... ... Perou CM, et al. DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. Npj Breast Cancer. 2: 16007. PMID 28721375 DOI: 10.1038/npjbcancer.2016.7  0.64
2016 Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, ... ... Perou CM, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer. 2. PMID 28691057 DOI: 10.1038/npjbcancer.2015.23  0.4
2016 Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 13: e1002174. PMID 27923045 DOI: 10.1371/journal.pmed.1002174  0.8
2016 Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodríguez J, Arcusa A, Chacón I, Sánchez-Rovira P, Plazaola A, Muñoz M, Paré L, Parker JS, Ribelles N, ... ... Perou CM, et al. A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903675 DOI: 10.1158/1078-0432.CCR-16-2092  0.8
2016 Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, ... ... Perou CM, et al. The molecular basis of breast cancer pathological phenotypes. The Journal of Pathology. PMID 27861902 DOI: 10.1002/path.4847  0.64
2016 Reaves DK, Hoadley KA, Fagan-Solis K, Jima DD, Bereman M, Thorpe L, Hicks J, McDonald D, Troester MA, Perou CM, Fleming JM. Nuclear localized LSR, a novel regulator of breast cancer behavior and tumorigenesis. Molecular Cancer Research : McR. PMID 27856957 DOI: 10.1158/1541-7786.MCR-16-0085-T  0.64
2016 Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C, Conzen SD, Zuley M, Net JM, Sutton E, Whitman GJ, Morris E, Perou CM, Ji Y, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. Npj Breast Cancer. 2. PMID 27853751 DOI: 10.1038/npjbcancer.2016.12  0.64
2016 Mose LE, Selitsky SR, Bixby LM, Marron DL, Iglesia MD, Serody JS, Perou CM, Vincent BG, Parker JS. Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. Bioinformatics (Oxford, England). PMID 27559159 DOI: 10.1093/bioinformatics/btw526  0.8
2016 Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute. 108. PMID 27335052 DOI: 10.1093/jnci/djw144  0.8
2016 Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor C, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell A, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, ... ... Perou CM, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27301700 DOI: 10.1158/1078-0432.CCR-16-0162  0.32
2016 Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, ... ... Perou CM, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 534: 55-62. PMID 27251275 DOI: 10.1038/nature18003  0.56
2016 Lawson CD, Fan C, Mitin N, Baker NM, George SD, Graham DM, Perou CM, Burridge K, Der CJ, Rossman KL. Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-activating Proteins in Basal-like Breast Cancers. Cancer Research. PMID 27216196 DOI: 10.1158/0008-5472.CAN-15-2923  0.52
2016 Pfefferle AD, Agrawal YN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, Rosen JM, Perou CM. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53 deficient mammary cancers. Disease Models & Mechanisms. PMID 27149990 DOI: 10.1242/dmm.025239  0.8
2016 Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, et al. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. Radiology. 152110. PMID 27144536 DOI: 10.1148/radiol.2016152110  0.64
2016 Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. Plos One. 11: e0150564. PMID 26991655 DOI: 10.1371/journal.pone.0150564  0.52
2016 Zhao W, Hoadley KA, Parker JS, Perou CM. Identification of mRNA isoform switching in breast cancer. Bmc Genomics. 17: 181. PMID 26939613 DOI: 10.1186/s12864-016-2521-9  0.8
2016 Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment. PMID 26909792 DOI: 10.1007/s10549-016-3725-z  0.32
2015 Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MC. αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. Npj Breast Cancer. 1. PMID 27656679 DOI: 10.1038/npjbcancer.2015.14  0.52
2015 Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O'Connor S, Tse CK, Bell MB, Hu Z, Li Y, ... ... Perou CM, et al. Performance of three biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26711328 DOI: 10.1158/1055-9965.EPI-15-0874  0.44
2015 Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Reports. PMID 26686626 DOI: 10.1016/j.celrep.2015.11.029  0.64
2015 Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. Bmc Medicine. 13: 303. PMID 26684470 DOI: 10.1186/s12916-015-0540-z  0.64
2015 Ruggles KV, Tang Z, Wang X, Grover H, Askenazi M, Teubl J, Cao S, McLellan MD, Clauser KR, Tabb DL, Mertins P, Slebos R, Erdmann-Gilmore P, Li S, Gunawardena HP, ... ... Perou CM, et al. An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer. Molecular & Cellular Proteomics : McP. PMID 26631509 DOI: 10.1074/mcp.M115.056226  0.64
2015 Hu YJ, Sun W, Tzeng JY, Perou CM. Proper Use of Allele-Specific Expression Improves Statistical Power for cis-eQTL Mapping with RNA-Seq Data. Journal of the American Statistical Association. 110: 962-974. PMID 26568645 DOI: 10.1080/01621459.2015.1038449  0.8
2015 Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, ... Perou CM, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527775 DOI: 10.1200/JCO.2015.62.1268  0.64
2015 Faruki H, Mayhew GM, Fan C, Wilkerson MD, Parker S, Kam-Morgan L, Eisenberg M, Horten B, Hayes DN, Perou CM, Lai-Goldman M. Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets. Archives of Pathology & Laboratory Medicine. PMID 26430809 DOI: 10.5858/arpa.2015-0113-OA  0.52
2015 Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, Perou CM, Wahl GM. Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells. Cell Reports. 12: 2035-48. PMID 26365194 DOI: 10.1016/j.celrep.2015.08.040  0.8
2015 Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, ... ... Perou CM, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. Bmc Medical Genomics. 8: 54. PMID 26297356 DOI: 10.1186/s12920-015-0129-6  0.8
2015 Parker JS, Perou CM. Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest? Cancer Cell. 28: 149-50. PMID 26267531 DOI: 10.1016/j.ccell.2015.07.011  0.8
2015 Carey LA, Perou CM. Palbociclib--Taking Breast-Cancer Cells Out of Gear. The New England Journal of Medicine. 373: 273-4. PMID 26176385 DOI: 10.1056/NEJMe1506680  0.8
2015 Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, Zwaka TP, Hilsenbeck SG, Medina D, Perou CM, Creighton CJ, et al. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Reports. PMID 26166574 DOI: 10.1016/j.celrep.2015.06.044  0.8
2015 Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute. 107. PMID 26113580 DOI: 10.1093/jnci/djv179  0.8
2015 Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Research and Treatment. PMID 26109346 DOI: 10.1007/s10549-015-3476-2  0.8
2015 D'Arcy M, Fleming J, Robinson WR, Kirk EL, Perou CM, Troester MA. Race-associated biological differences among Luminal A breast tumors. Breast Cancer Research and Treatment. PMID 26109344 DOI: 10.1007/s10549-015-3474-4  0.44
2015 Black JL, Harrell JC, Leisner TM, Fellmeth MJ, George SD, Reinhold D, Baker NM, Jones CD, Der CJ, Perou CM, Parise LV. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 26105795 DOI: 10.1007/s10549-015-3458-4  0.8
2015 Cantrell MA, Ebelt ND, Pfefferle AD, Perou CM, Van Den Berg CL. c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression. Oncotarget. 6: 11863-81. PMID 25970777 DOI: 10.18632/oncotarget.3787  0.8
2015 Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, ... ... Perou CM, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/mcp.M115.049783  0.8
2015 Schott AF, Perou CM, Hayes DF. Genome Medicine in Cancer: What's in a Name? Cancer Research. 75: 1930-5. PMID 25920349 DOI: 10.1158/0008-5472.CAN-15-0174  0.8
2015 Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, ... ... Perou CM, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. The Oncologist. 20: 474-82. PMID 25908555 DOI: 10.1634/theoncologist.2014-0372  0.8
2015 Nielsen TO, Perou CM. CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1779-81. PMID 25878358 DOI: 10.1158/1078-0432.CCR-14-2552  0.8
2015 Wagenblast E, Soto M, Gutiérrez-Ángel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, Harrell JC, Smith AD, Perou CM, Wilkinson JE, Hannon GJ, et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 520: 358-62. PMID 25855289 DOI: 10.1038/nature14403  0.8
2015 Welch JD, Baran-Gale J, Perou CM, Sethupathy P, Prins JF. Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential. Bmc Genomics. 16: 113. PMID 25765044 DOI: 10.1186/s12864-015-1227-8  0.8
2015 Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discovery. 5: 520-33. PMID 25735774 DOI: 10.1158/2159-8290.CD-14-1101  0.8
2015 He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, Darr DB, Perou CM, Jordan R, Ojima I, Kabanov AV, Luxenhofer R. Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 208: 67-75. PMID 25725361 DOI: 10.1016/j.jconrel.2015.02.024  0.8
2015 Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. Response. Journal of the National Cancer Institute. 107. PMID 25717172 DOI: 10.1093/jnci/djv029  0.8
2015 . Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 517: 576-82. PMID 25631445 DOI: 10.1038/nature14129  0.8
2015 Pfefferle AD, Spike BT, Wahl GM, Perou CM. Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 149: 425-37. PMID 25575446 DOI: 10.1007/s10549-014-3262-6  0.8
2015 Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, et al. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. Journal of the National Cancer Institute. 107. PMID 25490892 DOI: 10.1093/jnci/dju401  0.8
2015 Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 81-8. PMID 25361981 DOI: 10.1093/annonc/mdu498  0.8
2015 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 13-21. PMID 25092775 DOI: 10.1200/JCO.2014.57.0572  0.8
2015 Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. Journal of Biopharmaceutical Statistics. 25: 66-88. PMID 24836519 DOI: 10.1080/10543406.2014.919933  0.8
2015 Couture HD, Marron JS, Thomas NE, Perou CM, Niethammer M. Hierarchical task-driven feature learning for tumor histology Proceedings - International Symposium On Biomedical Imaging. 2015: 999-1003. DOI: 10.1109/ISBI.2015.7164039  0.8
2015 Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AAA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, ... ... Perou CM, et al. Progesterone receptor modulates ERα action in breast cancer Nature. 523: 313-317. DOI: 10.1038/nature14583  0.8
2014 Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, Perou CM, Liu H. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Research. 74: 7406-17. PMID 25339353 DOI: 10.1158/0008-5472.CAN-14-1188  0.8
2014 Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortés J, Baselga J, Perou CM, Prat A, et al. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. Journal of the National Cancer Institute. 106. PMID 25253614 DOI: 10.1093/jnci/dju291  0.32
2014 Bai F, Chan HL, Scott A, Smith MD, Fan C, Herschkowitz JI, Perou CM, Livingstone AS, Robbins DJ, Capobianco AJ, Pei XH. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. Cancer Research. 74: 6161-72. PMID 25239453 DOI: 10.1158/0008-5472.CAN-14-1119  0.8
2014 Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6083-95. PMID 25231403 DOI: 10.1158/1078-0432.CCR-14-0493  0.8
2014 Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nature Genetics. 46: 1051-9. PMID 25151356 DOI: 10.1038/ng.3073  0.8
2014 Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. The Oncologist. 19: 1076-83. PMID 25142841 DOI: 10.1634/theoncologist.2014-0184  0.8
2014 Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Journal of the National Cancer Institute. 106. PMID 25139534 DOI: 10.1093/jnci/dju152  0.8
2014 Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? Journal of the National Cancer Institute. 106. PMID 25118203 DOI: 10.1093/jnci/dju165  0.8
2014 Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, ... ... Perou CM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 158: 929-44. PMID 25109877 DOI: 10.1016/j.cell.2014.06.049  0.8
2014 Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, ... ... Perou CM, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer. 111: 1532-41. PMID 25101563 DOI: 10.1038/bjc.2014.444  0.8
2014 Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Research and Treatment. 147: 185-91. PMID 25048467 DOI: 10.1007/s10549-014-3056-x  0.8
2014 Kimes PK, Cabanski CR, Wilkerson MD, Zhao N, Johnson AR, Perou CM, Makowski L, Maher CA, Liu Y, Marron JS, Hayes DN. SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples. Nucleic Acids Research. 42: e113. PMID 25030904 DOI: 10.1093/nar/gku521  0.8
2014 Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, ... ... Perou CM, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Research and Treatment. 146: 557-66. PMID 25001612 DOI: 10.1007/s10549-014-3039-y  0.8
2014 Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, Troester MA, Hammerman PS, Parker JS, Perou CM, Hayes DN. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Research. 42: e107. PMID 24970867 DOI: 10.1093/nar/gku489  0.8
2014 Phillips S, Prat A, Sedic M, Proia T, Wronski A, Mazumdar S, Skibinski A, Shirley SH, Perou CM, Gill G, Gupta PB, Kuperwasser C. Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports. 2: 633-47. PMID 24936451 DOI: 10.1016/j.stemcr.2014.03.008  0.8
2014 Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3818-29. PMID 24916698 DOI: 10.1158/1078-0432.CCR-13-3368  0.8
2014 Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (Oxford, England). 30: 2813-5. PMID 24907369 DOI: 10.1093/bioinformatics/btu376  0.8
2014 Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. Bmc Genomics. 15: 419. PMID 24888378 DOI: 10.1186/1471-2164-15-419  0.8
2014 Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, ... ... Perou CM, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science Signaling. 7: ra29. PMID 24667376 DOI: 10.1126/scisignal.2005125  0.8
2014 Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 144: 503-17. PMID 24567196 DOI: 10.1007/s10549-014-2887-9  0.8
2014 Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, ... ... Perou C, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 384: 164-72. PMID 24529560 DOI: 10.1016/S0140-6736(13)62422-8  0.8
2014 Oh DS, Cheang MC, Fan C, Perou CM. Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Radiation Research. 181: 193-207. PMID 24527691 DOI: 10.1667/RR13485.1  0.8
2014 Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, Miller CR, Jin J, Darr D, Perou CM, Levine RL, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. The Journal of Clinical Investigation. 124: 553-63. PMID 24435044 DOI: 10.1172/JCI69804  0.8
2014 Xiao L, Harrell JC, Perou CM, Dudley AC. Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro. Angiogenesis. 17: 511-8. PMID 24257808 DOI: 10.1007/s10456-013-9409-y  0.8
2014 Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, ... ... Perou CM, et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 33: 3992-4002. PMID 24056965 DOI: 10.1038/onc.2013.368  0.8
2014 Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clinical & Experimental Metastasis. 31: 33-45. PMID 23975155 DOI: 10.1007/s10585-013-9607-4  0.8
2014 Romero A, Prat A, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 16: 386-94. PMID 23907291 DOI: 10.1007/s12094-013-1088-z  0.8
2014 Singh N, Couture HD, Marron JS, Perou C, Niethammer M. Topological descriptors of histology images Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 8679: 231-239.  0.8
2013 Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biology. 14: R125. PMID 24220145 DOI: 10.1186/gb-2013-14-11-r125  0.8
2013 Sundaram S, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA, Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Research and Treatment. 142: 489-503. PMID 24218051 DOI: 10.1007/s10549-013-2741-5  0.8
2013 Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Research and Treatment. 142: 365-80. PMID 24212716 DOI: 10.1007/s10549-013-2738-0  0.8
2013 Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Research and Treatment. 142: 237-55. PMID 24162158 DOI: 10.1007/s10549-013-2743-3  0.8
2013 Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Perou CM, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/j.cell.2013.09.034  0.8
2013 Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N. The molecular diversity of Luminal A breast tumors. Breast Cancer Research and Treatment. 141: 409-20. PMID 24096568 DOI: 10.1007/s10549-013-2699-3  0.8
2013 Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, ... ... Perou CM, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports. 4: 1116-30. PMID 24055055 DOI: 10.1016/j.celrep.2013.08.022  0.8
2013 Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, et al. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. The Journal of Clinical Investigation. 123: 4329-43. PMID 23999432 DOI: 10.1172/JCI66764  0.8
2013 Chen K, Navin NE, Wang Y, Schmidt HK, Wallis JW, Niu B, Fan X, Zhao H, McLellan MD, Hoadley KA, Mardis ER, Ley TJ, Perou CM, Wilson RK, Ding L. BreakTrans: uncovering the genomic architecture of gene fusions. Genome Biology. 14: R87. PMID 23972288 DOI: 10.1186/gb-2013-14-8-r87  0.8
2013 Prat A, Martin M, Nielsen TO, Perou CM. Reply to Y.Yamamoto et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2517-8. PMID 23967491 DOI: 10.1200/JCO.2013.49.9061  0.8
2013 Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 14372-7. PMID 23940356 DOI: 10.1073/pnas.1303204110  0.8
2013 Cabanski CR, Wilkerson MD, Soloway M, Parker JS, Liu J, Prins JF, Marron JS, Perou CM, Hayes DN. BlackOPs: increasing confidence in variant detection through mappability filtering. Nucleic Acids Research. 41: e178. PMID 23935067 DOI: 10.1093/nar/gkt692  0.8
2013 Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2206-23. PMID 23917950 DOI: 10.1093/annonc/mdt303  0.8
2013 Richards KL, Motsinger-Reif AA, Chen HW, Fedoriw Y, Fan C, Nielsen DM, Small GW, Thomas R, Smith C, Dave SS, Perou CM, Breen M, Borst LB, Suter SE. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Research. 73: 5029-39. PMID 23783577 DOI: 10.1158/0008-5472.CAN-12-3546  0.8
2013 Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, ... ... Perou CM, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4889-99. PMID 23780888 DOI: 10.1158/1078-0432.CCR-13-0522  0.8
2013 Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, ... ... Perou CM, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Research. 73: 4885-97. PMID 23737486 DOI: 10.1158/0008-5472.CAN-12-4081  0.8
2013 Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Molecular and Cellular Biology. 33: 3011-25. PMID 23716599 DOI: 10.1128/MCB.01443-12  0.8
2013 Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 1438-50. PMID 23702728 DOI: 10.1038/modpathol.2013.97  0.8
2013 Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, ... Perou CM, et al. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. The Journal of Molecular Diagnostics : Jmd. 15: 485-97. PMID 23701907 DOI: 10.1016/j.jmoldx.2013.03.007  0.8
2013 Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. Plos One. 8: e61359. PMID 23650496 DOI: 10.1371/journal.pone.0061359  0.8
2013 Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 497: 67-73. PMID 23636398 DOI: 10.1038/nature12113  0.8
2013 Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Research. 73: 4075-85. PMID 23633485 DOI: 10.1158/0008-5472.CAN-12-4579  0.8
2013 Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, ... ... Perou CM, et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Research and Treatment. 138: 457-66. PMID 23423445 DOI: 10.1007/s10549-013-2416-2  0.8
2013 Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist. 18: 123-33. PMID 23404817 DOI: 10.1634/theoncologist.2012-0397  0.8
2013 Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nature Communications. 4: 1449. PMID 23385593 DOI: 10.1038/ncomms2438  0.8
2013 Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Young Park S, Eileen Dolan M, Perou CM, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 Nature Communications. 4. PMID 23340433 DOI: 10.1038/ncomms2393  0.8
2013 Nguyen DH, Fredlund E, Zhao W, Perou CM, Balmain A, Mao JH, Barcellos-Hoff MH. Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1353-62. PMID 23339125 DOI: 10.1158/1078-0432.CCR-12-3554  0.8
2013 Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discovery. 3: 27-34. PMID 23319768 DOI: 10.1158/2159-8290.CD-12-0462  0.8
2013 Ulirsch J, Fan C, Knafl G, Wu MJ, Coleman B, Perou CM, Swift-Scanlan T. Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Research and Treatment. 137: 383-96. PMID 23239149 DOI: 10.1007/s10549-012-2353-5  0.8
2013 Brauer HA, Makowski L, Hoadley KA, Casbas-Hernandez P, Lang LJ, Romàn-Pèrez E, D'Arcy M, Freemerman AJ, Perou CM, Troester MA. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 571-85. PMID 23236214 DOI: 10.1158/1078-0432.CCR-12-2123  0.8
2013 Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 203-9. PMID 23233704 DOI: 10.1200/JCO.2012.43.4134  0.8
2013 Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion Breast Cancer Research and Treatment. 137: 373-382. PMID 23224145 DOI: 10.1007/s10549-012-2346-4  0.8
2013 Huang H, Liu Y, Du Y, Perou CM, Neil Hayes D, Todd MJ, Marron JS. Multiclass distance-weighted discrimination Journal of Computational and Graphical Statistics. 22: 953-969. DOI: 10.1080/10618600.2012.700878  0.8
2012 Smith BA, Shelton DN, Kieffer C, Milash B, Usary J, Perou CM, Bernard PS, Welm BE. Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. Genes & Cancer. 3: 550-63. PMID 23486760 DOI: 10.1177/1947601913475359  0.8
2012 Chao HH, He X, Parker JS, Zhao W, Perou CM. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. Plos One. 7: e51719. PMID 23284754 DOI: 10.1371/journal.pone.0051719  0.8
2012 Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, ... ... Perou CM, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. Bmc Medical Genomics. 5: 44. PMID 23035882 DOI: 10.1186/1755-8794-5-44  0.8
2012 Cabanski CR, Cavin K, Bizon C, Wilkerson MD, Parker JS, Wilhelmsen KC, Perou CM, Marron JS, Hayes DN. ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data. Bmc Bioinformatics. 13: 221. PMID 22946927 DOI: 10.1186/1471-2105-13-221  0.8
2012 Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.CCR-12-0563  0.8
2012 Wallace MD, Pfefferle AD, Shen L, McNairn AJ, Cerami EG, Fallon BL, Rinaldi VD, Southard TL, Perou CM, Schimenti JC. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics. 192: 385-96. PMID 22851646 DOI: 10.1534/genetics.112.142802  0.8
2012 Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Research and Treatment. 135: 301-6. PMID 22752290 DOI: 10.1007/s10549-012-2143-0  0.8
2012 Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4465-72. PMID 22711706 DOI: 10.1158/1078-0432.CCR-12-0286  0.8
2012 Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 21: 751-64. PMID 22698401 DOI: 10.1016/j.ccr.2012.03.048  0.8
2012 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, ... ... Perou CM, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2615-23. PMID 22665533 DOI: 10.1200/JCO.2010.34.5579  0.8
2012 Xu K, Usary J, Kousis PC, Prat A, Wang DY, Adams JR, Wang W, Loch AJ, Deng T, Zhao W, Cardiff RD, Yoon K, Gaiano N, Ling V, Beyene J, ... ... Perou CM, et al. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell. 21: 626-41. PMID 22624713 DOI: 10.1016/j.ccr.2012.03.041  0.8
2012 Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, ... Perou CM, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. Plos One. 7: e36530. PMID 22590557 DOI: 10.1371/journal.pone.0036530  0.8
2012 Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, Hursting SD. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prevention Research (Philadelphia, Pa.). 5: 930-42. PMID 22588949 DOI: 10.1158/1940-6207.CAPR-12-0034  0.8
2012 Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS. Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Research. 72: 3260-9. PMID 22552288 DOI: 10.1158/0008-5472.CAN-11-4141  0.8
2012 Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2866-73. PMID 22532584 DOI: 10.1093/annonc/mds080  0.8
2012 Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... ... Perou CM, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/j.cell.2012.02.053  0.8
2012 Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. Plos One. 7: e34546. PMID 22479643 DOI: 10.1371/journal.pone.0034546  0.8
2012 Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, ... ... Perou CM, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2402-12. PMID 22351696 DOI: 10.1158/1078-0432.CCR-11-2956  0.8
2012 Iraqi FA, Mahajne M, Salaymah Y, Sandovski H, Tayem H, Vered K, Balmer L, Hall M, Manship G, Morahan G, Pettit K, Scholten J, Tweedie K, Wallace A, Weerasekera L, ... ... Perou CM, et al. The genome architecture of the collaborative cross mouse genetic reference population Genetics. 190: 389-401. PMID 22345608 DOI: 10.1534/genetics.111.132639  0.8
2012 Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. Journal of the National Cancer Institute. 104: 476-87. PMID 22302033 DOI: 10.1093/jnci/djs002  0.8
2012 Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62. PMID 22198468 DOI: 10.1007/s10549-011-1895-2  0.8
2012 Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America. 109: 221-6. PMID 22178756 DOI: 10.1073/pnas.1115802109  0.8
2012 Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nature Reviews. Clinical Oncology. 9: 48-57. PMID 22143140 DOI: 10.1038/nrclinonc.2011.178  0.8
2012 Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Research and Treatment. 133: 865-80. PMID 22048815 DOI: 10.1007/s10549-011-1846-y  0.8
2012 Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkilä P, Perou CM, Horwitz KB. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Academy of Sciences of the United States of America. 109: 2742-7. PMID 21969591 DOI: 10.1073/pnas.1106509108  0.8
2012 Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C. Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2772-7. PMID 21940501 DOI: 10.1073/pnas.1017626108  0.8
2012 Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proceedings of the National Academy of Sciences of the United States of America. 109: 2802-7. PMID 21908711 DOI: 10.1073/pnas.1108781108  0.8
2012 Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Research and Treatment. 132: 523-35. PMID 21671017 DOI: 10.1007/s10549-011-1619-7  0.8
2012 Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 2778-83. PMID 21633010 DOI: 10.1073/pnas.1018862108  0.8
2012 Glück S, Ross JS, Royce M, McKenna EF, Perou CM, Avisar E, Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Research and Treatment. 132: 781-91. PMID 21373875 DOI: 10.1007/s10549-011-1412-7  0.8
2011 Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, et al. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. Bmc Medical Genomics. 4: 77. PMID 22044755 DOI: 10.1186/1755-8794-4-77  0.8
2011 Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, ... ... Perou CM, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature Genetics. 43: 1210-4. PMID 22037553 DOI: 10.1038/ng.985  0.8
2011 Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell. 8: 525-37. PMID 21549327 DOI: 10.1016/j.stem.2011.03.008  0.8
2011 Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle (Georgetown, Tex.). 10: 1563-70. PMID 21502814 DOI: 10.4161/cc.10.10.15703  0.8
2011 Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 117: 1602-11. PMID 21472708 DOI: 10.1002/cncr.25746  0.8
2011 Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, ... ... Perou CM, et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Research and Treatment. 128: 127-36. PMID 21465170 DOI: 10.1007/s10549-011-1461-y  0.8
2011 Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, Smith IE, Dowsett M. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids. 76: 736-40. PMID 21447351 DOI: 10.1016/j.steroids.2011.02.025  0.8
2011 Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. The American Journal of Pathology. 178: 1453-60. PMID 21435434 DOI: 10.1016/j.ajpath.2010.12.042  0.8
2011 Perou CM. Molecular stratification of triple-negative breast cancers. The Oncologist. 16: 61-70. PMID 21278442 DOI: 10.1634/theoncologist.2011-S1-61  0.8
2011 Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. Bmc Medical Genomics. 4: 3. PMID 21214954 DOI: 10.1186/1755-8794-4-3  0.8
2011 Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular Oncology. 5: 5-23. PMID 21147047 DOI: 10.1016/j.molonc.2010.11.003  0.8
2011 Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Molecular Cancer Research : McR. 9: 3-13. PMID 21131600 DOI: 10.1158/1541-7786.MCR-10-0372  0.8
2011 Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18-20. PMID 21115855 DOI: 10.1200/JCO.2010.28.9199  0.8
2011 Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harbor Perspectives in Biology. 3. PMID 21047916 DOI: 10.1101/cshperspect.a003293  0.8
2011 Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS, Molinolo A, Perou CM, Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Research and Treatment. 129: 49-67. PMID 20890655 DOI: 10.1007/s10549-010-1185-4  0.8
2011 Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer Breast Cancer Research. 13. DOI: 10.1186/bcr2909  0.8
2010 O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6100-10. PMID 21169259 DOI: 10.1158/1078-0432.CCR-10-1533  0.8
2010 Perou CM. Molecular stratification of triple-negative breast cancers. The Oncologist. 15: 39-48. PMID 21138954 DOI: 10.1634/theoncologist.2010-S5-39  0.8
2010 Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. Plos One. 5: e13073. PMID 20949095 DOI: 10.1371/journal.pone.0013073  0.8
2010 Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5222-32. PMID 20837693 DOI: 10.1158/1078-0432.CCR-10-1282  0.8
2010 Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN. Allele-specific copy number analysis of tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 16910-5. PMID 20837533 DOI: 10.1073/pnas.1009843107  0.8
2010 Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research : Bcr. 12: R68. PMID 20813035 DOI: 10.1186/bcr2635  0.8
2010 Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, Mieczkowski P, Grimm SA, Perou CM, MacLeod JN, Chiang DY, Prins JF, Liu J. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Research. 38: e178. PMID 20802226 DOI: 10.1093/nar/gkq622  0.8
2010 Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. The Lancet. Oncology. 11: 718-9; author reply . PMID 20688274 DOI: 10.1016/S1470-2045(10)70176-5  0.8
2010 Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. The Journal of Clinical Investigation. 120: 3296-309. PMID 20679727 DOI: 10.1172/JCI41490  0.8
2010 Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, ... ... Perou CM, et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. Plos Medicine. 7: e1000307. PMID 20644708 DOI: 10.1371/journal.pmed.1000307  0.8
2010 Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, ... ... Perou CM, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4864-75. PMID 20643781 DOI: 10.1158/1078-0432.CCR-10-0199  0.8
2010 Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y. Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Molecular and Cellular Biology. 30: 3981-93. PMID 20547751 DOI: 10.1128/MCB.01284-09  0.8
2010 Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Research. 70: 4868-79. PMID 20501844 DOI: 10.1158/0008-5472.CAN-09-4404  0.8
2010 Prat A, Perou CM. WITHDRAWN: Deconstructing the molecular portraits of breast cancer. Molecular Oncology. PMID 20447881 DOI: 10.1016/j.molonc.2010.04.003  0.32
2010 Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17: 510-22. PMID 20399149 DOI: 10.1016/j.ccr.2010.03.017  0.8
2010 Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, ... ... Perou CM, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 464: 999-1005. PMID 20393555 DOI: 10.1038/nature08989  0.8
2010 Cabanski CR, Qi Y, Yin X, Bair E, Hayward MC, Fan C, Li J, Wilkerson MD, Marron JS, Perou CM, Hayes DN. SWISS MADE: Standardized WithIn Class Sum of Squares to evaluate methodologies and dataset elements. Plos One. 5: e9905. PMID 20360852 DOI: 10.1371/journal.pone.0009905  0.8
2010 Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, ... ... Perou CM, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110. PMID 20129251 DOI: 10.1016/j.ccr.2009.12.020  0.8
2010 Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1161-7. PMID 20124184 DOI: 10.1200/JCO.2009.23.9616  0.8
2009 Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS. Activation of host wound responses in breast cancer microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7020-8. PMID 19887484 DOI: 10.1158/1078-0432.CCR-09-1126  0.8
2009 Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, ... ... Perou CM, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4515-21. PMID 19704069 DOI: 10.1200/JCO.2008.19.6873  0.8
2009 Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. Plos One. 4: e6693. PMID 19690609 DOI: 10.1371/journal.pone.0006693  0.8
2009 Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, ... ... Perou CM, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America. 106: 13820-5. PMID 19666588 DOI: 10.1073/pnas.0905718106  0.8
2009 Prat A, Perou CM. Mammary development meets cancer genomics. Nature Medicine. 15: 842-4. PMID 19661985 DOI: 10.1038/nm0809-842  0.8
2009 Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Research : Bcr. 11: R55. PMID 19638211 DOI: 10.1186/bcr2344  0.8
2009 Sun W, Wright FA, Tang Z, Nordgard SH, Van Loo P, Yu T, Kristensen VN, Perou CM. Integrated study of copy number states and genotype calls using high-density SNP arrays Nucleic Acids Research. 37: 5365-5377. PMID 19581427 DOI: 10.1093/nar/gkp493  0.8
2009 DiMeo TA, Anderson K, Phadke P, Fan C, Feng C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Research. 69: 5364-73. PMID 19549913 DOI: 10.1158/0008-5472.CAN-08-4135  0.8
2009 Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 15: 539-50. PMID 19477432 DOI: 10.1016/j.ccr.2009.03.027  0.8
2009 Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, Livasy C, Ketelsen D, Nepal DB, Perou CM, Patterson C, Klauber-DeMore N. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway Cancer Research. 69: 4621-4628. PMID 19458075 DOI: 10.1158/0008-5472.CAN-08-3402  0.8
2009 Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 101: 736-50. PMID 19436038 DOI: 10.1093/jnci/djp082  0.8
2009 Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, ... ... Perou CM, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research. 69: 4116-24. PMID 19435916 DOI: 10.1158/0008-5472.CAN-08-3441  0.8
2009 Pei XH, Bai F, Smith MD, Usary J, Fan C, Pai SY, Ho IC, Perou CM, Xiong Y. CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell. 15: 389-401. PMID 19411068 DOI: 10.1016/j.ccr.2009.03.004  0.8
2009 Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA, Watson MA, Saporita A, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Research. 69: 3955-62. PMID 19366795 DOI: 10.1158/0008-5472.CAN-08-4450  0.8
2009 Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM. A compact VEGF signature associated with distant metastases and poor outcomes. Bmc Medicine. 7: 9. PMID 19291283 DOI: 10.1186/1741-7015-7-9  0.8
2009 Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1168-76. PMID 19204205 DOI: 10.1200/JCO.2008.18.1024  0.8
2009 Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, ... ... Perou CM, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1160-7. PMID 19204204 DOI: 10.1200/JCO.2008.18.1370  0.8
2009 Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 28: 742-51. PMID 19043454 DOI: 10.1038/onc.2008.430  0.8
2009 Shabalin AA, Weigman VJ, Perou CM, Nobel AB. Finding large average submatrices in high dimensional data Annals of Applied Statistics. 3: 985-1012. DOI: 10.1214/09-AOAS239  0.8
2009 DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer (Cancer Research (2009) 69 (5364-5373)) Cancer Research. 69: 6366. DOI: 10.1158/0008-5472.CAN-69-15-COR2  0.8
2009 Nielsen TO, Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Bernard PS, Perou CM, Ellis MJ. Response: Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer Journal of the National Cancer Institute. 101: 1730-1731. DOI: 10.1093/jnci/djp391  0.8
2009 Liu X, Parker J, Fan C, Perou CM, Marron JS. Visualization of Cross-Platform Microarray Normalization Batch Effects and Noise in Microarray Experiments: Sources and Solutions. 167-181. DOI: 10.1002/9780470685983.ch14  0.52
2008 Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Research : Bcr. 10: R75. PMID 18782450 DOI: 10.1186/bcr2142  0.8
2008 Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L. Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Molecular Cancer. 7: 29. PMID 18394172 DOI: 10.1186/1476-4598-7-29  0.8
2008 Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B, ... Perou CM, et al. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. British Journal of Cancer. 98: 1327-35. PMID 18382427 DOI: 10.1038/sj.bjc.6604322  0.52
2008 Bultman SJ, Herschkowitz JI, Godfrey V, Gebuhr TC, Yaniv M, Perou CM, Magnuson T. Characterization of mammary tumors from Brg1 heterozygous mice Oncogene. 27: 460-468. PMID 17637742 DOI: 10.1038/sj.onc.1210664  0.8
2007 Jiang J, Parker CE, Hoadley KA, Perou CM, Boysen G, Borchers CH. Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics. Clinical Applications. 1: 1651-9. PMID 21136662 DOI: 10.1002/prca.200700009  0.8
2007 Li Z, Tognon CE, Godinho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim SJ, Bronson RT, Perou CM, Sorensen PH, Orkin SH. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell. 12: 542-58. PMID 18068631 DOI: 10.1016/j.ccr.2007.11.012  0.8
2007 Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM. EGFR associated expression profiles vary with breast tumor subtype. Bmc Genomics. 8: 258. PMID 17663798 DOI: 10.1186/1471-2164-8-258  0.8
2007 Burkart MF, Wren JD, Herschkowitz JI, Perou CM, Garner HR. Clustering microarray-derived gene lists through implicit literature relationships. Bioinformatics (Oxford, England). 23: 1995-2003. PMID 17537751 DOI: 10.1093/bioinformatics/btm261  0.8
2007 Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, ... ... Perou CM, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology. 8: R76. PMID 17493263 DOI: 10.1186/gb-2007-8-5-r76  0.8
2007 Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, Sandler RS, Sharpless NE. RNA expression analysis of formalin-fixed paraffin-embedded tumors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 383-91. PMID 17297435 DOI: 10.1038/labinvest.3700529  0.8
2006 Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM. Gene expression patterns associated with p53 status in breast cancer. Bmc Cancer. 6: 276. PMID 17150101 DOI: 10.1186/1471-2407-6-276  0.8
2006 Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. The New England Journal of Medicine. 355: 560-9. PMID 16899776 DOI: 10.1056/NEJMoa052933  0.52
2006 Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, ... ... Perou CM, et al. The molecular portraits of breast tumors are conserved across microarray platforms. Bmc Genomics. 7: 96. PMID 16643655 DOI: 10.1186/1471-2164-7-96  0.8
2006 Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1656-64. PMID 16505416 DOI: 10.1200/JCO.2005.03.2755  0.8
2004 Troester MA, Hoadley KA, Parker JS, Perou CM. Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environmental Health Perspectives. 112: 1607-13. PMID 15598611 DOI: 10.1289/txg.7204  0.8
2004 Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale AL, Perou CM. Mutation of GATA3 in human breast tumors. Oncogene. 23: 7669-78. PMID 15361840 DOI: 10.1038/sj.onc.1207966  0.8
2004 Troester MA, Hoadley KA, Sørlie T, Herbert BS, Børresen-Dale AL, Lønning PE, Shay JW, Kaufmann WK, Perou CM. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Research. 64: 4218-26. PMID 15205334 DOI: 10.1158/0008-5472.CAN-04-0107  0.8
2004 Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, ... Perou CM, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 5: 489-500. PMID 15144956 DOI: 10.1016/S1535-6108(04)00112-6  0.8
Show low-probability matches.